Verteporfin photodynamic therapy as monotherapy may be considered medically necessary as a treatment of choroidal neovascularization associated with age-related macular degeneration, pathologic myopia, presumed ocular histoplasmosis, chronic central serous chorioretinopathy, or choroidal hemangioma.
Verteporfin photodynamic therapy is considered investigational as monotherapy for other ophthalmologic disorders.
Verteporfin photodynamic therapy is considered investigational when used in combination with one or more of the antivascular endothelial growth factor therapies: pegaptanib (Macugen®), ranibizumab (Lucentis®), bevacizumab (Avastin®), or aflibercept (Eylea™) as a treatment of choroidal neovascularization associated with age-related macular degeneration, pathologic myopia, presumed ocular histoplasmosis, central serous chorioretinopathy, choroidal hemangioma, or for other ophthalmologic disorders.
